Literature DB >> 26649873

Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".

Guo-Fu Li1, Xiao Gu2, Guo Yu3,4, Shui-Yu Zhao5, Qing-Shan Zheng6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26649873     DOI： 10.1007/s40262-015-0348-1

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  27 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Duodenal bile acids in infancy.

Authors:  D N Challacombe; S Edkins; G A Brown
Journal:  Arch Dis Child       Date:  1975-11       Impact factor: 3.791

3.  Cerebral blood flow in patients with chronic heart failure before and after heart transplantation.

Authors:  N Gruhn; F S Larsen; S Boesgaard; G M Knudsen; S A Mortensen; G Thomsen; J Aldershvile
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

4.  Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol.

Authors:  L D Carlton; G M Pollack; K L Brouwer
Journal:  J Pharm Sci       Date:  1996-05       Impact factor: 3.534

5.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Drug absorption VII: influence of mesenteric blood flow on intestinal drug absorption in dogs.

Authors:  W G Crouthamel; L Diamond; L W Dittert; J T Doluisio
Journal:  J Pharm Sci       Date:  1975-04       Impact factor: 3.534

7.  Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure.

Authors:  M E Leithe; R D Margorien; J B Hermiller; D V Unverferth; C V Leier
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

Review 8.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

Authors:  Masoud Jamei; Gemma L Dickinson; Amin Rostami-Hodjegan
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

9.  A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.

Authors:  Muhammad Fawad Rasool; Feras Khalil; Stephanie Läer
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

10.  Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry.

Authors:  M Rowland
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-10
View more
  3 in total

1.  Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.

Authors:  Guo-Fu Li; Qing-Shan Zheng; Yichao Yu; Wei Zhong; Hong-Hao Zhou; Furong Qiu; Guangji Wang; Guo Yu; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

2.  Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective.

Authors:  Guo-Fu Li; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

3.  Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Authors:  R B Verheijen; L E Swart; J H Beijnen; J H M Schellens; A D R Huitema; N Steeghs
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-19       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.